190 related articles for article (PubMed ID: 23518212)
1. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation.
Conde D; Costabel JP; Caro M; Ferro A; Lambardi F; Corrales Barboza A; Lavalle Cobo A; Trivi M
Int J Cardiol; 2013 Oct; 168(3):2423-5. PubMed ID: 23518212
[TBL] [Abstract][Full Text] [Related]
2. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.
Conde D; Costabel JP; Aragon M; Lambardi F; Klein A; Corrales Barbosa A; Trivi M; Giniger A
Cardiovasc Ther; 2013 Dec; 31(6):377-80. PubMed ID: 23683253
[TBL] [Abstract][Full Text] [Related]
3. Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
Conde D; Costabel JP; Aragon M; Lambardi F; Trivi M
Cardiol J; 2014; 21(3):304-8. PubMed ID: 23990184
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
Simon A; Niederdoeckl J; Skyllouriotis E; Schuetz N; Herkner H; Weiser C; Laggner AN; Domanovits H; Spiel AO
Europace; 2017 Feb; 19(2):233-240. PubMed ID: 28175295
[TBL] [Abstract][Full Text] [Related]
5. Conversion of Recent-Onset Atrial Fibrillation: Which Drug is the Best?
Conde D; Elissamburu P; Lalor N; Rodriguez L; Aragon M; Costabel JP; Lambardi F; Trivi M
J Atr Fibrillation; 2013; 6(2):910. PubMed ID: 28496882
[No Abstract] [Full Text] [Related]
6. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
Conde D
Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
8. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
10. Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
Conde D; Costabel JP; Aragon M; Caro M; Ferro A; Klein A; Trivi M; Giniger A
Can J Cardiol; 2013 Oct; 29(10):1330.e13. PubMed ID: 23465347
[No Abstract] [Full Text] [Related]
11. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
[TBL] [Abstract][Full Text] [Related]
12. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
Stoneman P; Gilligan P; Mahon P; Sheahan R
Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
[TBL] [Abstract][Full Text] [Related]
13. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
14. Predictors of conversion of recent-onset atrial fibrillation treated with vernakalant.
Costabel JP; Lambardi F; Aragón M; Campos R; Urdapilleta M; Ariznavarreta P; Vergara JM; Conde D
Pacing Clin Electrophysiol; 2015 Feb; 38(2):196-200. PubMed ID: 25469647
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
[TBL] [Abstract][Full Text] [Related]
18. Vernakalant hydrochloride to treat atrial fibrillation.
Brown RA; Lau YC; Lip GY
Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
20. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
